PR Newswire: news distribution, targeting and monitoring
 

First Painless Laser Treatment for Acne Introduced

 
 

Aesthera's Isolaz (Deep Pore Lazr Therapy) with Photopneumatic technology

offers novel pore purification to clear widest range of acne types



    PLEASANTON, Calif., May 22 /PRNewswire/ -- Aesthera Corporation, the
 pioneer of technologically advanced PhotopneumaticTM (PPx(TM)) aesthetic
 systems, announced today the arrival of its newest painless laser therapy -
 Isolaz(TM) (Deep Pore Lazr Therapy) - into the consumer marketplace.
 Powered by Photopneumatic Technology, the Isolaz helps destroy acne causing
 bacteria with a combination of pneumatic energy (vacuum) and laser light
 for a dramatic pore purifying therapy that helps clears acne fast.
     Aesthera's Isolaz(TM) (Deep Pore Lazr Therapy) offers the broadest
 indications of any laser or light-based system available on the market
 today and is the only system FDA cleared to treat comedonal and pustular
 acne. In addition, the Isolaz(TM) therapy is cleared to treat mild to
 moderate, inflammatory acne and acne vulgaris.
     In addition to acne reduction, a recent clinical study showed that 64
 percent of acne patients who had not responded to oral medications,
 topicals and traditional lasers in the past had shown greater than a 75
 percent clearance of acne lesions after treatment with the Isolaz(TM)
 system (i). After four treatments, an 88 percent reduction in papular,
 pustular, comedonal and nodular acne was observed(ii).
     "The Isolaz(TM) treatment is the new gold-standard that physicians and
 consumers should look to when treating acne, as it is the only technology
 that literally cleans the pores from the inside out," states Alon Maor,
 Co-Founder, President & CEO of Aesthera Corporation. "In contrast to
 traditional therapies, because the Isolaz system deep purifies the pores,
 many patients experience immediate gratification with noticeably clearer
 skin tone and texture as well as reduced pore size after the first
 treatment."
     Patients that undergo Isolaz(TM) (Deep Pore Lazr Therapy) do not
 experience side effects commonly associated with lasers and acne
 treatments, such as redness, peeling or sun sensitivity. Additionally,
 immediate improvements are generally seen within the 24-48 hours of the
 first Isolaz(TM) treatment including a drying and flattening of the lesion.
 Finally, Isolaz treatments are fast and can be performed in around 10
 minutes so you can have them done during lunch. Isolaz(TM) treatments also
 do not require pre- treatment and/or topical anesthetics.
     Along with being cleared for acne, the Isolaz(TM) is also FDA cleared
 for the treatment of vascular and pigmented lesions as well as permanent
 hair reduction.
     Isolaz(TM) acne therapy is offered on all of Aesthera's Isolaz(TM) and
 PPx(TM) systems. Currently there are over 1000 systems available worldwide.
 To learn were you can receive an Isolaz(TM) treatment or if you would like
 to receive more information on the Isolaz(TM) System please call
 877.275.4779, email WeListen@AESTHERA.com or visit www.ISOLAZ.com.
     About Aesthera Corporation
     Aesthera (www.AESTHERA.com) develops, manufactures and markets
 light-based aesthetic treatment systems based on proprietary
 Photopneumatic(TM) (PPx(TM)) technology. Clinically proven to be pain-free
 and up to seven times faster than currently available light-based aesthetic
 systems, Aesthera's revolutionary systems combine the proven properties of
 therapeutic light with gentle pneumatic energy to more effectively work on
 dermal and epidermal skin targets. Aesthera allows physicians to provide
 powerfully painless aesthetic treatments in a system with very low
 cost-to-own and near-immediate profitability -- giving them the opportunity
 to provide best-in-class service.
     i. Photopneumatic (PPx) Pore-Cleansing Acne Treatment: A breakthrough
 treatment option for Non-Responders to Acne Therapies, Ava T. Shamban, MD,
 Laser Institute for Dermatology and European Skin Care, Santa Monica, CA,
 October 2006.
     ii. Multi-Center Data submitted to FDA, Aesthera Corporation, July
 2006.
 
 

SOURCE Aesthera Corporation
Back to top

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

Featured Video

 
  • Print
  • Email
  •   RSS
  • Share it  
  • Blog it  
  • Blog Search  

More in These Categories

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Free Investing Newsletter from Investor Uprising!

Learn to navigate the world's financial system and profit from leading companies.  

Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All That Glitters: The Ultimate Gold Report".

Advanced Search
Search
  
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire